Are there functional β 3-adrenoceptors in the human heart?

British Journal of Pharmacology

Volumn 162, Issue 4, 2011, Pages 817-822

  Michel, Martin C ^a   Harding, Sian E ^b   Bond, Richard A ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY OF HOUSTON   (United States)

Author keywords

3 adrenoceptors; calcium current; heart, human; inotropy

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 1 (3,4 DIHYDROXYPHENOXY) 3 (3,4 DIMETHOXYPHENETHYLAMINO) 2 PROPANOL; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; AMIBEGRON; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BUCINDOLOL; BUPRANOLOL; CALCIUM CHANNEL L TYPE; CYANOPINDOLOL; CYCLIC AMP; L 748337; MESSENGER RNA; METOPROLOL; MIRABEGRON; NADOLOL; NEBIVOLOL; NITRIC OXIDE SYNTHASE; PROPRANOLOL; SOLABEGRON; UNCLASSIFIED DRUG;

BINDING AFFINITY; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SELECTIVITY; DRUG SENSITIVITY; HEART ATRIUM CONTRACTILITY; HEART ATRIUM CONTRACTION; HEART VENTRICLE CONTRACTILITY; HUMAN; INOTROPISM; NONHUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; HEART; HEART CONTRACTION; HEART MUSCLE; METABOLISM; NOTE;

ADRENERGIC BETA-3 RECEPTOR AGONISTS; ADRENERGIC BETA-3 RECEPTOR ANTAGONISTS; CALCIUM CHANNELS, L-TYPE; HEART; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIUM; RECEPTORS, ADRENERGIC, BETA-3;

EID: 79251524213     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01005.x     Document Type: Review

References (44)

1. Arch JRS, (2008). Perspectives from β3-adrenoceptor agonists on pharmacology, physiology and obesity drug discovery. Naunyn Schmiedebergs Arch Pharmacol 378: 225-240.
2. 3 and atypical β-adrenoceptors. Med Res Rev 13: 663-729.
3. Baker JG, (2005). The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Br J Pharmacol 144: 317-322.
4. 3- adrenoceptors. Br J Pharmacol 160: 1048-1061.
5. Bianchetti A, Manara L, (1990). In vitro inhibition of intestinal motility by phenylethanolaminetetralines: evidence of atypical β-adrenoceptors in rat colon. Br J Pharmacol 100: 831-839.
6. 2- adrenoceptors mediating relaxation in rat isolated aorta. Br J Pharmacol 138: 99-106.
7. 3-adrenoceptor-induced eNOS activation in right atrial and left ventricular human myocardium. Br J Pharmacol 143: 1014-1022.
8. Brodde O-E, Michel MC, (1999). Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 51: 651-689.
9. 1-adrenoceptors in human myocardium. J Pharmacol Exp Ther 300: 794-801.
10. 3-adrenergic receptor antagonists. J Pharmacol Exp Ther 290: 649-655.
11. 3- adrenoceptor in human adipose tissue, atrium and skeletal muscle. Int J Obes Relat Metab Disord 23: 1057-1065.
12. Chapple CR, Yamaguchi O, Ridder A, Liehne J, Carl S, Mattiasson A, et al. (2008). Clinical proof of concept study (Blossom) shows novel β3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol Suppl 7: 239.
13. Chapple C, Wyndaele J-J, van Kerrebroeck P, Radziszewski P, Dvorak V, Boerrigter P, (2010). Dose-ranging study of once-daily mirabegron (YM178), a novel selective β3-adrenoceptor agonist, in patients with overactive bladder (OAB). Eur Urol Suppl 9: 249.
14. 2+ current at physiological temperature. Br J Pharmacol 162: 823-829.
15. 3-adrenergic receptor. Science 245: 1118-1121.
16. Evans BA, Sato M, Sarwar M, Hutchinson DS, Summers RJ, (2010). Ligand-directed signalling at β-adrenoceptors. Br J Pharmacol 159: 1022-1038.
17. Galindo-Tovar A, Vargas ML, Kaumann AJ, (2009). Phosphodiesterases PDE3 and PDE4 jointly control the inotropic effects but not chronotropic effects of (-)-CGP12177 despite PDE4-evoked sinoatrial bradycardia in rat atrium. Naunyn Schmiedebergs Arch Pharmacol 379: 379-384.
18. 3-adrenoceptor in the human heart. J Clin Invest 98: 556-562.
19. 3-adrenoceptor agonists. J Pharmacol Exp Ther 290: 687-693.
20. 2-adrenoceptors in human heart. Differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (-)-noradrenaline and (-)-adrenaline. Naunyn Schmiedebergs Arch Pharmacol 331: 60-70.
21. 3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. Am J Physiol 294: G1114-G1119.
22. Hamdani N, van der Velden J, (2009). Lack of specificity of antibodies directed against human beta-adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 379: 403-407.
23. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz K-N, (2004). Comparative pharmacology of human β-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 369: 151-159.
24. 2-adrenoceptors in the isolated human right atrium. Naunyn Schmiedebergs Arch Pharmacol 335: 561-566.
25. Kaumann AJ, Molenaar P, (1997). Modulation of human cardiac function through 4 β-adrenoceptor populations. Naunyn Schmiedebergs Arch Pharmacol 355: 667-681.
26. 1-adrenoceptor and its relevance to cardiovascular pharmacology. Pharmacol Ther 118: 303-336.
27. 3- adrenoceptors and coupled to a cyclic AMP-dependent pathway in human and rat myocardium. Br J Pharmacol 120 (Suppl): 102P.
28. Krief S, Lönnqvist F, Raimbault S, Baude B, van Spronsen A, Arner P, et al. (1993). Tissue distribution of beta 3-adrenergic receptor mRNA in man. J Clin Invest 91: 344-349.
29. Michel MC, Alewijnse AE, (2007). Ligand-directed signaling: 50 ways to find a lover. Mol Pharmacol 72: 1097-1099.
30. Moens AL, Yang R, Watts VL, Barouch LA, (2010). Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system. J Mol Cell Cardiol 48: 1088-1095.
31. 3-adrenoceptors. Br J Pharmacol 120: 165-176.
32. 3-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 103: 1649-1655.
33. Moniotte S, Vaerman J-L, Kockx MM, Larrouy D, Langin D, Noirhomme P, et al. (2001b). Real-time RT-PCR for the detection of beta-adrenoceptor messenger RNAs in small human endomyocardial biopsies. J Mol Cell Cardiol 33: 2121-2133.
34. 3-adrenoceptors in rat retinal blood vessels. Naunyn Schmiedebergs Arch Pharmacol 382: 119-126.
35. 3-adrenergic agonist BRL 37344 on endothelial nitric oxide synthase phosphorylation and force of contraction in human failing myocardium. J Card Fail 15: 57-67.
36. 2-Adrenoceptors and non-β-adrenoceptors mediate effects of BRL37344 and clenbuterol on glucose uptake in soleus muscle: studies using knockout mice. Br J Pharmacol 158: 1676-1682.
37. 3-adrenoceptors in human atrial myocardium. Br J Pharmacol 138: 521-529.
38. Pradidarcheep W, Stallen J, Labruyere WT, Dabhoiwala NF, Michel MC, Lamers WH, (2009). Lack of specificity of commercially available antisera against muscarinic and adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 379: 397-402.
39. 3-Adrenoceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol Ther 111: 652-673.
40. 3-adrenoceptor agonist in the nonfailing transplanted heart. J Am Coll Cardiol 53: 1532-1538.
41. 3-adreoceptor agonists of differing selectivities. J Pharmacol Exp Ther 285: 1084-1095.
42. 2+ current. J Clin Invest 118: 3219-3227.
43. 3- adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 374: 385-398.
44. 3-adrenoceptors? Br J Pharmacol 156: 127-134.